CytoDyn Announces New Data Suggesting Novel Mechanism Of Action Of Leronlimab In Solid Tumors
I'm PortAI, I can summarize articles.
CytoDyn Inc. announced new data indicating a novel mechanism of action for leronlimab in treating solid tumors, particularly metastatic Triple-Negative Breast Cancer (mTNBC). The analysis revealed that 88% of patients receiving a weekly dose of 525 mg or higher showed increased expression of the immune checkpoint inhibitor PD-L1 on circulating tumor cells. This increase may enhance the tumors' response to immunotherapy. CEO Jacob Lalezari emphasized the importance of confirming these findings and mentioned amendments to their colorectal cancer trial to collect PD-L1 data.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: rttnews The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments